We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Device Compared to Thromboelastography for Clotting Defects

By LabMedica International staff writers
Posted on 09 Jul 2020
Print article
Image: A novel LSR-based coagulation sensor called iCoagLab has been favorably compared to thromboelastography to estimate bleeding risk (Photo courtesy of Massachusetts General Hospital).
Image: A novel LSR-based coagulation sensor called iCoagLab has been favorably compared to thromboelastography to estimate bleeding risk (Photo courtesy of Massachusetts General Hospital).
Clotting disorders occur when the body is unable to make sufficient amounts of the proteins that are needed to help the blood clot, stopping bleeding. These proteins are called clotting factors (coagulation factors). All clotting factors are made in the liver which requires vitamin K to make some of the clotting factors.

Delayed identification of coagulopathy and bleeding increases the risk of organ failure and death in hospitalized patients. Timely and accurate identification of impaired coagulation at the point-of-care can proactively identify bleeding risk and guide resuscitation, resulting in improved outcomes for patients.

Photomedicine Scientists at the Massachusetts General Hospital (Boston, MA, USA) and their medical colleagues tested the accuracy of a novel optical coagulation sensing approach, termed iCoagLab, for comprehensive whole blood coagulation profiling and investigate its diagnostic accuracy in identifying patients at elevated bleeding risk. Whole blood samples from 270 patients undergoing conventional coagulation testing were measured using the iCoagLab device. The iCoagLab test involves the use of an inexpensive laser that can illuminate a few drops of blood taken from a patient. Fluctuations made visible by the laser indicate whether the blood can properly clot.

The iCoagLab instrument was based on the principles of laser speckle rheology (LSR), a recent optical approach that measures the viscoelastic properties of soft tissues from laser speckle pattern. Recalcified and kaolin-activated blood samples were loaded in disposable cartridges and time-varying intensity fluctuation of laser speckle patterns were measured to quantify the clot viscoelastic modulus during coagulation. Coagulation parameters including the reaction time (R), clot progression time (K), clot progression rate (α), and maximum clot strength (MA) were derived from clot viscoelasticity traces and compared with mechanical thromboelastography (TEG).

In all patients, a good correlation between iCoagLab- and TEG-derived parameters was observed. Multivariate analysis showed that iCoagLab-derived parameters identified bleeding risk with sensitivity of 94%, identical to TEG, and diagnostic accuracy (89%) that was higher than TEG (87%). The diagnostic specificity of iCoagLab (77%) was significantly higher than TEG (69%).

Seemantini K. Nadkarni, PhD, an associate professor and senior author of the study, said, “Clinicians in the operating room or the ICU often walk a thin line to maintain the delicate balance between bleeding and coagulation. The iCoagLab innovation will likely advance clinical capability to rapidly identify patients with defective clotting at the point-of-care, assess risk of hemorrhage, and tailor treatments based on individual coagulation deficits to help prevent life-threatening bleeding in patients.”

The authors concluded that by rapidly and comprehensively permitting blood coagulation profiling the iCoagLab innovation is likely to advance the capability to identify patients with elevated risk for bleeding, with the ultimate goal of preventing life-threatening hemorrhage. The study was published on June 22, 2020 in the journal Thrombosis and Haemostasis.

Related Links:
Massachusetts General Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.